RXDX Prometheus Biosciences

Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference

Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference

SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that Mark McKenna, President and CEO, will participate virtually in a fireside chat during the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55 a.m. ET.

A live and archived webcast of the virtual fireside chat will be available via the section of the Prometheus Biosciences .

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of immune-mediated diseases, starting first with IBD. The Company’s precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.  Prometheus is headquartered in San Diego, CA.

Contacts:

Noel Kurdi

VP Investor Relations and Communications

(646) 241-4400

 

Media contact:

Juniper Point

Amy Conrad

(858) 914-1962

 



EN
14/05/2021

Underlying

RXDXPrometheus Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prometheus Biosciences

Jonathan Moreland
  • Jonathan Moreland
Free Trial
OXY Occidental Petr...
MASI Masimo Corporat... ... (+47)

InsiderInsights Weekly Report: June 3, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

OXY OCCIDENTAL PETROLEUM CORPORATION
MASI MASIMO CORPORATION
TCBI TEXAS CAPITAL BANCSHARES INC.
RYAM RAYONIER ADVANCED MATERIALS INC
NSTG NANOSTRING TECHNOLOGIES
GCO GENESCO INC.
CAPL CROSSAMERICA PARTNERS LP
BOH BANK OF HAWAII CORPORATION
BIG BIG LOTS INC.
ALGN ALIGN TECHNOLOGY INC.
ABR ARBOR REALTY TRUST INC.
SAFT SAFETY INSURANCE GROUP INC.
EVRI EVERI HOLDINGS INC.
ADC AGREE REALTY CORPORATION
ET ENERGY TRANSFER L.P.
NSA NATIONAL STORAGE AFFILIATES TRUST
OVLY OAK VALLEY BANCORP
FBK FB FINANCIAL CORPORATION
NNBR NN
CNX INC.
PRPL CONSOL ENERGY INC.
DOMO PURPLE INNOVATION
HHC INC.
INVA DOMO INCORPORATED
SAFE THE HOWARD HUGHES CORPORATION
BW INOVA TECH
PINE SAFEHOLD INC.
CMCT BABCOCK & WILCOX ENTERPRISES
DHC ALPINE INCOME PROPERTY TRUST
TCRR CIM COMMERCIAL TRUST CORPORATION
ORCC DIVERSIFIED HEALTHCARE TRUST
LYRA TCR2 THERAPEUTICS INC.
CPE OWL ROCK CAPITAL CORP
ADV LYRA THERAPEUTICS
ANNX INC.
ABCL CALLON PETROLEUM
DRVN ADVANTAGE SOLUTIONS INC (A)
NRGX ANNEXON
RXDX ABCELLERA BIOLOGICS
GEG DRIVEN BRANDS HOLDINGS
LFMD PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
AUID PROMETHEUS BIOSCIENCES
EMO GREAT ELM GROUP INC
LIFEMD
INC.
IPSIDY INC.
CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
06/04/23 June 4, 2023 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TLYS TILLYS
MTDR Matador Resourc... ... (+25)

InsiderInsights.com Daily Ratings Report: June 2, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TLYS TILLYS
MTDR MATADOR RESOURCES COMPANY
HIBB HIBBETT SPORTS INC.
BIG BIG LOTS INC.
ABR ARBOR REALTY TRUST INC.
SAFT SAFETY INSURANCE GROUP INC.
TTEC TELETECH HOLDINGS
FBK INC.
SNAP FB FINANCIAL CORPORATION
BCBP SNAP INC. CLASS A
FRPH BCB BANCORP INC.
DOMO FRP HOLDINGS INC
BFST DOMO INCORPORATED
HHC BUSINESS FIRST BANCSHARES
BW THE HOWARD HUGHES CORPORATION
PINE BABCOCK & WILCOX ENTERPRISES
LYRA ALPINE INCOME PROPERTY TRUST
CPE LYRA THERAPEUTICS
PUBM INC.
TERN CALLON PETROLEUM
SNSE PUBMATIC
RXDX TERNS PHARMACEUTICALS
ATNF SENSEI BIOTHERAPEUTICS
PROMETHEUS BIOSCIENCES
180 LIFE SCIENCES CORP
06/03/23 June 3, 2023 1 EN
 PRESS RELEASE
Free
RXDX Prometheus Bios...

Prometheus Biosciences Reports First Quarter 2023 Financial Results an...

Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress - Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 - SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 20...

May 9, 2023 1 EN
 PRESS RELEASE
Free
RXDX Prometheus Bios...

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus B...

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology RAHWAY, N.J. and SAN DIEGO, April 16, 2023 (GLOBE NEWSWIRE) -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into...

April 16, 2023 1 EN
 PRESS RELEASE
Free
RXDX Prometheus Bios...

Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healt...

Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 10:40 AM ET. A live and archived webcast of the fireside chat will be available via the page on the Investor section of ...

March 9, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch